The Impact of Reproductive Issues on Preferences of Women with Relapsing Multiple Sclerosis for Disease-Modifying Treatments

被引:6
|
作者
Webb, Edward J. D. [1 ]
Meads, David M. [1 ]
Eskyte, Ieva [2 ]
Ford, Helen L. [3 ]
Bekker, Hilary L. [1 ]
Chataway, Jeremy [4 ,5 ]
Pepper, George [6 ]
Marti, Joachim [7 ]
Okan, Yasmina [8 ]
Pavitt, Sue H. [9 ]
Schmierer, Klaus [10 ,11 ]
Manzano, Ana [12 ]
机构
[1] Univ Leeds, Leeds Inst Hlth Sci, Leeds, W Yorkshire, England
[2] Univ Leeds, Sch Law, Leeds, W Yorkshire, England
[3] Leeds Teaching Hosp NHS Trust, Leeds, W Yorkshire, England
[4] UCL, Queen Sq Multiple Sclerosis Ctr, Dept Neuroinflammat, UCL Queen Sq Inst Neurol,Fac Brain Sci, London WC1B 5EH, England
[5] Univ Coll London Hosp, Biomed Res Ctr, Natl Inst Hlth Res, London, England
[6] ShiftMs, London, England
[7] Univ Lausanne, Ctr Primary Care & Publ Hlth Unisante, Lausanne, Switzerland
[8] Univ Leeds, Leeds Univ, Ctr Decis Res, Business Sch, Leeds, W Yorkshire, England
[9] Univ Leeds, Sch Dent, Dent Translat & Clin Res Unit, Leeds, W Yorkshire, England
[10] Queen Mary Univ London, Barts & London Sch Med & Dent, Blizard Inst Neurosci Surg & Trauma, London, England
[11] Barts Hlth NHS Trust, Royal London Hosp, Clin Board Med Neurosci, London, England
[12] Univ Leeds, Sch Sociol & Social Policy, Leeds, W Yorkshire, England
来源
关键词
DISCRETE-CHOICE EXPERIMENTS; CONJOINT-ANALYSIS; PROFESSIONALS PREFERENCES; PATIENT PREFERENCES; PREGNANCY; THERAPIES; DIAGNOSIS; ATTRIBUTES; PEOPLE; TESTS;
D O I
10.1007/s40271-020-00429-4
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Background Relapsing-remitting multiple sclerosis (RRMS) is an incurable disease characterised by relapses (periods of function loss) followed by full or partial recovery, and potential permanent disability over time. Many disease-modifying treatments (DMTs) exist that help reduce relapses and slow disease progression. Most are contraindicated during conception/pregnancy and some require a discontinuation period before trying to conceive. Although around three-quarters of people with RRMS are women, there is limited knowledge about how reproductive issues impact DMT preference. Objective The aim of this study was to measure the preferences for DMTs of women with RRMS who are considering pregnancy. Design An online discrete choice experiment (DCE). Methods Participants chose between two hypothetical DMTs characterised by a set of attributes, then indicated if they preferred their choice to no treatment. Attributes were identified from interviews and focus groups with people with RRMS and MS professionals, as well as literature reviews, and included the probability of problems with pregnancy, discontinuation of DMTs, and breastfeeding safety. In each DCE task, participants were asked to imagine making decisions in three scenarios: now; when trying to conceive; and when pregnant. Analysis Two mixed logit models were estimated, one to assess the statistical significance between scenarios and one in maximum acceptable risk space to allow comparison of the magnitudes of parameters between scenarios. Sample Women with RRMS who were considering having a child in the future, recruited from a UK MS patient register. Results Sixty respondents completed the survey. Participants preferred no treatment in 12.6% of choices in the 'now' scenario, rising significantly to 37.6% in the 'trying to conceive' scenario and 60.3% in the 'pregnant' scenario (Kruskal-Wallisp < 0.001). This pattern corresponds with results from models that included a no-treatment alternative-specific constant (ASC) capturing differences between taking and not taking a DMT not specified by the attributes. The ASC was lower in the trying to conceive scenario than in the now scenario, and lower still in the pregnant scenario, indicating an intrinsic preference for no treatment. Participants also placed relatively less preference on reducing relapses and avoiding disease progression in the trying to conceive and pregnant scenarios compared with a lower risk of problems with pregnancy. In the trying to conceive scenario, participants' preference for treatments with shorter washout periods increased. Conclusion Women with RRMS considering having a child prefer DMTs with more favourable reproduction-related attributes, even when not trying to conceive. Reproductive issues also influenced preferences for DMT attributes not directly related to pregnancy, with preferences dependent on the life circumstances in which choices were made. The design of the DCE highlights the benefits of considering the scenario in which participants make choices, as they may change over time.
引用
收藏
页码:583 / 597
页数:15
相关论文
共 50 条
  • [21] Stopping disease-modifying therapy in relapsing and progressive multiple sclerosis
    Hartung, Hans-Peter
    Meuth, Sven G.
    Miller, Deborah M.
    Comi, Giancarlo
    CURRENT OPINION IN NEUROLOGY, 2021, 34 (04) : 598 - 603
  • [22] Impact of disease-modifying treatments in North African migrants with multiple sclerosis in France
    Lebrun, C.
    Debouverie, M.
    Jeannin, S.
    Pittion-Vouyovitch, S.
    Bayreuther, C.
    Berthier, F.
    MULTIPLE SCLEROSIS JOURNAL, 2008, 14 (07) : 933 - 939
  • [23] Decision Making About Disease-Modifying Treatments for Relapsing-Remitting Multiple Sclerosis: Stated Preferences and Real-World Choices
    Webb, Edward J. D.
    Meads, David
    Eskyte, Ieva
    Ford, Helen L.
    Bekker, Hilary L.
    Chataway, Jeremy
    Pepper, George
    Marti, Joachim
    Okan, Yasmina
    Pavitt, Sue H.
    Schmierer, Klaus
    Manzano, Ana
    PATIENT-PATIENT CENTERED OUTCOMES RESEARCH, 2023, 16 (05): : 457 - 471
  • [24] Decision Making About Disease-Modifying Treatments for Relapsing-Remitting Multiple Sclerosis: Stated Preferences and Real-World Choices
    Edward J. D. Webb
    David Meads
    Ieva Eskytė
    Helen L. Ford
    Hilary L. Bekker
    Jeremy Chataway
    George Pepper
    Joachim Marti
    Yasmina Okan
    Sue H. Pavitt
    Klaus Schmierer
    Ana Manzano
    The Patient - Patient-Centered Outcomes Research, 2023, 16 : 457 - 471
  • [25] Oral Disease-Modifying Treatments for Relapsing Multiple Sclerosis: A Likelihood to Achieve No Evidence of Disease Activity or Harm Analysis
    Dimitrios Papadopoulos
    Dimos-Dimitrios D. Mitsikostas
    CNS Drugs, 2018, 32 : 1069 - 1078
  • [26] Highly active disease and access to disease-modifying treatments in patients with relapsing-remitting multiple sclerosis in Poland
    Brola, Waldemar
    Adamczyk-Sowa, Monika
    Kulakowska, Alina
    Glazewska, Joanna
    Smaga, Anna
    Bartosik-Psujek, Halina
    NEUROLOGIA I NEUROCHIRURGIA POLSKA, 2022, 56 (03) : 256 - 260
  • [27] Oral Disease-Modifying Treatments for Relapsing Multiple Sclerosis: A Likelihood to Achieve No Evidence of Disease Activity or Harm Analysis
    Papadopoulos, Dimitrios
    Mitsikostas, Dimos-Dimitrios D.
    CNS DRUGS, 2018, 32 (11) : 1069 - 1078
  • [28] Cost-utility of First-line Disease-modifying Treatments for Relapsing Remitting Multiple Sclerosis
    Soini, Erkki
    Joutseno, Jaana
    Sumelahti, Marja-Liisa
    CLINICAL THERAPEUTICS, 2017, 39 (03) : 537 - +
  • [29] Modelling the Cost Effectiveness of Disease-Modifying Treatments for Multiple Sclerosis
    Thompson, Joel P.
    Abdolahi, Amir
    Noyes, Katia
    PHARMACOECONOMICS, 2013, 31 (06) : 455 - 469
  • [30] Adherence to disease-modifying treatments in patients with multiple sclerosis in Spain
    Morillo Verdugo, Ramon
    Ramirez Herraiz, Esther
    Fernandez-Del Olmo, Raquel
    Roig Bonet, Montserrat
    Valdivia Garcia, Maria
    PATIENT PREFERENCE AND ADHERENCE, 2019, 13 : 261 - 272